Neurocrine's Ingrezza brings 'clinically meaningful improvements' in older people with tardive dyskinesia

US biopharma company Neurocrine Biosciences has presented new data from its movement disorder program for tardive dyskinesia at the 2021 Psych Congress scientific meeting.

The data are on Ingrezza (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that is approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia.

New pooled analysis from the KINECT clinical trial program and long-term extension studies found that long-term use of the drug led to substantial and clinically meaningful improvements in patients of at least 65 years with tardive dyskinesia, some of the first VMAT2 inhibitor data for patients in this age group with the disorder.